# Lanifibranor PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/lanifibranor

> The FDA approved lanifibranor, sponsored by Inventiva S.A. (IVA), on June 2, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is lanifibranor FDA approved?

Yes. The FDA approved lanifibranor, sponsored by Inventiva S.A. (IVA), on June 2, 2026. Press release filed with the SEC (EX-99): "On June 2, 2026, we entered into a subscription agreement with funds and accounts managed by BlackRock and Claret Capital Partners (the "Lenders") providing for the issuance of new senior secured debt instruments for an aggregate committed principal amount of up to €130.0 million, plus an additional uncommitted tranche of up to €20.0 million subject to mutual consent following FDA approval of the NDA for lanifibranor (the "Subscription Agreement") (together, the "Debt Financing Transaction")." [Calendar and source filings](https://sec-api.dev/pdufa/lanifibranor)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-111143, https://www.sec.gov/Archives/edgar/data/1756594/000110465926111143/iva-20260630xex99d1.htm (retrieved 2026-11-12). Last confirmed 2026-09-28. Cite: https://sec-api.dev/pdufa/lanifibranor#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | lanifibranor |
| Codes | IVA337 |
| Sponsor | Inventiva S.A. (IVA) https://sec-api.dev/companies/iva/catalysts |
| Indications | [nafld and t2d](https://sec-api.dev/indications/nafld-and-t2d), t2d and nafld, non-alcoholic fatty liver disease, or nafld, and t2d, t2d and nafld sponsored, with mash with moderate and advanced fibrosis, with topline results, with mash, [NASH - Nonalcoholic Steatohepatitis](https://sec-api.dev/indications/nash-nonalcoholic-steatohepatitis) |
| Modality |  |
| FDA designations | breakthrough, fast track |

## Timeline

### June 13, 2023: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2. Indication: NAFLD and T2D.
- First seen 2025-04-15, last confirmed 2026-04-08.
- SEC Form 10-K (accession 0001104659-26-040704): "On June 13, 2023, the Company announced positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD." https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm
- SEC Form 10-K (accession 0001104659-25-035122): "On June 13, 2023, the Company announced positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD." https://www.sec.gov/Archives/edgar/data/1756594/000110465925035122/iva-20241231x20f.htm
- SEC Form 10-K (accession 0001104659-26-040704): "In June 2023, we announced positive topline results of the investigator-initiated Phase 2 clinical trial evaluating lanifibranor in patients with NAFLD and T2D. The Phase 2 clinical trial randomized 38 patients into two arms, with patients receiving placebo or treatment with lanifibranor at 800mg/day for 24 weeks." https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm
- SEC prospectus (424B) (accession 0001104659-25-111403): "In June 2023, we announced positive topline results of the investigator-initiated Phase 2 clinical trial evaluating lanifibranor in patients with Non-Alcoholic Fatty Liver Disease, or NAFLD, and T2D. The Phase 2 clinical trial randomized 38 patients into two arms, with patients receiving placebo or treatment with lanifibranor at 800mg/day for 24 weeks." https://www.sec.gov/Archives/edgar/data/1756594/000110465925111403/tm2528355-6_424b5.htm
- SEC prospectus (424B) (accession 0001104659-25-110422): "In June 2023, we announced positive topline results of the investigator-initiated Phase 2 clinical trial evaluating lanifibranor in patients with Non-Alcoholic Fatty Liver Disease, or NAFLD, and T2D. The Phase 2 clinical trial randomized 38 patients into two arms, with patients receiving placebo or treatment with lanifibranor at 800mg/day for 24 weeks." https://www.sec.gov/Archives/edgar/data/1756594/000110465925110422/tm2528355-4_424b5.htm
- SEC Form 10-K (accession 0001104659-25-035122): "In June 2023, we announced positive topline results of the investigator-initiated Phase 2 clinical trial evaluating lanifibranor in patients with NAFLD and T2D. The Phase 2 clinical trial randomized 38 patients into two arms, with patients receiving placebo or treatment with lanifibranor at 800mg/day for 24 weeks." https://www.sec.gov/Archives/edgar/data/1756594/000110465925035122/iva-20241231x20f.htm

### June 13, 2023: trial start

- Status: completed. Date confidence: exact. Stage: 2. Indication: NAFLD and T2D.
- First seen 2025-04-15, last confirmed 2026-04-08.
- SEC Form 10-K (accession 0001104659-26-040704): "On June 13, 2023, the Company announced positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD." https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm
- SEC Form 10-K (accession 0001104659-25-035122): "On June 13, 2023, the Company announced positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD." https://www.sec.gov/Archives/edgar/data/1756594/000110465925035122/iva-20241231x20f.htm
- SEC Form 10-K (accession 0001104659-26-040704): "In June 2023, we announced positive topline results of the investigator-initiated Phase 2 clinical trial evaluating lanifibranor in patients with NAFLD and T2D. The Phase 2 clinical trial randomized 38 patients into two arms, with patients receiving placebo or treatment with lanifibranor at 800mg/day for 24 weeks." https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm
- SEC prospectus (424B) (accession 0001104659-25-111403): "In June 2023, we announced positive topline results of the investigator-initiated Phase 2 clinical trial evaluating lanifibranor in patients with Non-Alcoholic Fatty Liver Disease, or NAFLD, and T2D. The Phase 2 clinical trial randomized 38 patients into two arms, with patients receiving placebo or treatment with lanifibranor at 800mg/day for 24 weeks." https://www.sec.gov/Archives/edgar/data/1756594/000110465925111403/tm2528355-6_424b5.htm
- SEC prospectus (424B) (accession 0001104659-25-110422): "In June 2023, we announced positive topline results of the investigator-initiated Phase 2 clinical trial evaluating lanifibranor in patients with Non-Alcoholic Fatty Liver Disease, or NAFLD, and T2D. The Phase 2 clinical trial randomized 38 patients into two arms, with patients receiving placebo or treatment with lanifibranor at 800mg/day for 24 weeks." https://www.sec.gov/Archives/edgar/data/1756594/000110465925110422/tm2528355-4_424b5.htm
- SEC Form 10-K (accession 0001104659-25-035122): "In June 2023, we announced positive topline results of the investigator-initiated Phase 2 clinical trial evaluating lanifibranor in patients with NAFLD and T2D. The Phase 2 clinical trial randomized 38 patients into two arms, with patients receiving placebo or treatment with lanifibranor at 800mg/day for 24 weeks." https://www.sec.gov/Archives/edgar/data/1756594/000110465925035122/iva-20241231x20f.htm
- SEC Form 10-K (accession 0001104659-26-040704): "Following the receipt of IND approval from the NMPA in May 2023, CTTQ decided to join our ongoing NATiV3 Phase 3 clinical trial with lanifibranor for the treatment of adult patients with MASH and has initiated a Phase 1 clinical pharmacology study in parallel." https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm
- SEC Form 10-K (accession 0001104659-25-035122): "Following the receipt of IND approval from the NMPA in May 2023, CTTQ decided to join our ongoing NATiV3 Phase 3 clinical trial with lanifibranor for the treatment of adult patients with MASH and has initiated a Phase 1 clinical pharmacology study in parallel." https://www.sec.gov/Archives/edgar/data/1756594/000110465925035122/iva-20241231x20f.htm
- SEC Form 10-K (accession 0001104659-25-035122): "Following the receipt of IND approval from the NMPA in May 2023, CTTQ decided to join the Company's ongoing NATiV3 Phase III clinical trial with lanifibranor for the treatment of adult patients with NASH and has initiated a Phase I clinical pharmacology study in parallel." https://www.sec.gov/Archives/edgar/data/1756594/000110465925035122/iva-20241231x20f.htm

### November 6, 2023: trial start

- Status: completed. Date confidence: exact. Stage: 2. Indication: T2D and NAFLD sponsored.
- First seen 2025-04-15, last confirmed 2026-04-08.
- SEC Form 10-K (accession 0001104659-26-040704): "On November 6, 2023, the Company announced a late breaker abstract that presents results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD sponsored by Dr. Cusi at the University of Florida." https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm
- SEC Form 10-K (accession 0001104659-25-035122): "On November 6, 2023, the Company announced a late breaker abstract that presents results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD sponsored by Dr. Cusi at the University of Florida." https://www.sec.gov/Archives/edgar/data/1756594/000110465925035122/iva-20241231x20f.htm

### June 2, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-09-28, last confirmed 2026-09-28.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-111143): "On June 2, 2026, we entered into a subscription agreement with funds and accounts managed by BlackRock and Claret Capital Partners (the "Lenders") providing for the issuance of new senior secured debt instruments for an aggregate committed principal amount of up to €130.0 million, plus an additional uncommitted tranche of up to €20.0 million subject to mutual consent following FDA approval of the NDA for lanifibranor (the "Subscription Agreement") (together, the "Debt Financing Transaction")." https://www.sec.gov/Archives/edgar/data/1756594/000110465926111143/iva-20260630xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-111143): "On June 2, 2026, the Company entered into a subscription agreement with funds and accounts managed by BlackRock and Claret Capital Partners (the "Lenders") providing for the issuance of new senior secured debt instruments for an aggregate committed principal amount of up to €130.0 million, plus an additional uncommitted tranche of up to €20.0 million subject to mutual consent following FDA approval of the NDA for lanifibranor (the "Subscription Agreement") (together, the "Debt Financing Transaction")." https://www.sec.gov/Archives/edgar/data/1756594/000110465926111143/iva-20260630xex99d1.htm

### September 29, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: NASH - Nonalcoholic Steatohepatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04849728 (A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-29 (ACTUAL); Lead Sponsor Inventiva Pharma." https://clinicaltrials.gov/study/NCT04849728

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: with MASH.
- First seen 2024-11-21, last confirmed 2026-11-16T22:20:01.192Z.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-001942): "With topline results expected in the second half of 2026, lanifibranor could potentially be the next oral therapy approved for the treatment of patients with MASH." https://www.sec.gov/Archives/edgar/data/1756594/000117184325001942/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-111143): "Following completion of the treatment period, we expect to report topline results in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1756594/000110465926111143/iva-20260630xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-111143): "Following completion of the treatment period, the Company expects to report topline results in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1756594/000110465926111143/iva-20260630xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-24-006512): "Topline results of NATiV3 - expected in the second half of 2026" https://www.sec.gov/Archives/edgar/data/1756594/000117184324006512/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-111143): "The publication of the topline results of NATiV3 is targeted for the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1756594/000110465926111143/iva-20260630xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-111143): "He will be responsible for leading our operational readiness as we approach the expected topline results from NATiV3 in the fourth quarter of 2026 and prepare for potential commercialization, subject to regulatory approvals." https://www.sec.gov/Archives/edgar/data/1756594/000110465926111143/iva-20260630xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-111143): "The publication of the topline results of the NATiV3 trial is targeted for the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1756594/000110465926111143/iva-20260630xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-111143): "He will be responsible for leading the Company's operational readiness as it approaches the expected topline results from NATiV3 in the fourth quarter of 2026 and prepare for potential commercialization, subject to regulatory approvals." https://www.sec.gov/Archives/edgar/data/1756594/000110465926111143/iva-20260630xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-001942): "Topline results from NATiV3 projected in the second half of 2026 and, if positive, expected to be the basis for submission for regulatory approval" https://www.sec.gov/Archives/edgar/data/1756594/000117184325001942/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-001942): "Topline results of NATiV3 are expected in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1756594/000117184325001942/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-001725): "Topline results of NATiV3 - expected in the second half of 2026" https://www.sec.gov/Archives/edgar/data/1756594/000117184325001725/exh_991.htm
- ClinicalTrials.gov: "NCT04849728 (A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-29 (ACTUAL); Lead Sponsor Inventiva Pharma." https://clinicaltrials.gov/study/NCT04849728

## Same indication

- [Rezdiffra (resmetirom)](https://sec-api.dev/pdufa/resmetirom) (MDGL)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/lanifibranor.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Lanifibranor PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/lanifibranor

```bibtex
@misc{secapidev_pdufa_lanifibranor_20261116,
  title        = {Lanifibranor PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/lanifibranor}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_lanifibranor_20261116","title":"Lanifibranor PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/lanifibranor","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
